**Core Concept:** Chronic myeloid leukemia (CML) is a type of cancer affecting the white blood cells, particularly granulocytes, due to a translocation of chromosomes 9 and 22 (Philadelphia chromosome). The BCR-ABL fusion gene encodes a constitutively active tyrosine kinase, which drives the disease progression. Treatment options aim to suppress the BCR-ABL kinase activity, leading to disease control.

**Why the Correct Answer is Right:** Imatinib (Gleevec) is the first-line treatment for chronic myeloid leukemia due to its high selectivity and potency against the BCR-ABL tyrosine kinase. It inhibits the activity of the fusion protein, leading to improved disease control and prolonged progression-free survival rates.

**Why Each Wrong Option is Incorrect:**

A. Hydroxyurea: A nucleoside analogue that primarily acts as an inhibitor of DNA synthesis, used in myeloproliferative disorders like polycythemia vera, but has minimal impact on BCR-ABL kinase activity.

B. Anagrelide: A selective inhibitor of platelet aggregation, primarily used in primary myelofibrosis. Unlike imatinib, it does not target BCR-ABL kinase activity, making it an unsuitable choice for CML treatment.

C. Interferon alpha: A cytokine used in the treatment of various viral infections and autoimmune diseases but lacks specific activity against BCR-ABL kinase, making it an ineffective choice for CML treatment.

D. Radiotherapy: A non-selective form of radiation therapy that damages DNA in dividing cells, including normal hematopoietic cells. Its use is limited due to significant side effects and lack of targeting BCR-ABL kinase.

**Clinical Pearl:** Imatinib is an effective targeted therapy for chronic myeloid leukemia, demonstrating superior outcomes compared to traditional cytotoxic therapies. It is a paradigm shift in cancer treatment, demonstrating the power of targeted therapy and personalized medicine.